New England Journal of Medicine· 2018Q1· Clinical trial
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- 3,545citations
- Q1SCImago
- 2018year
Short summary
Adding alirocumab to high-intensity statin therapy significantly reduced the risk of recurrent ischemic cardiovascular events by 15% in patients who recently experienced an acute coronary syndrome.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Surgery
SurgeryMedicine